Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the TD Cowen 45th Annual Healthcare Conference on Wednesday, March 5 at 8:50am PT / 11:50am ET. A live audio webcast will be available here: https://ow.ly/KbjM50VaqOA
Halozyme, Inc.
生物技术研究
San Diego，California 20,049 位关注者
At Halozyme we continuously push the pace of innovation.
关于我们
Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE? technology, which can reduce hours-long treatments to a matter of minutes, Halozyme's commercially-validated solution has positively impacted more than 400,000 patient lives via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE? technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE? technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the company's partners make progress developing and commercializing their products being developed with ENHANZE?. We are a diverse team, who are committed to bringing therapies and results to patients. It's not enough to be qualified and experienced at what you do, we are looking for people who believe in our mission and match our values. We are building a company where people can pursue their career goals in a supportive and collaborative team environment. Visit www.halozyme.com/careers for more details. We are Halozyme.
- 网站
-
https://www.halozyme.com
Halozyme, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 201-500 人
- 总部
- San Diego，California
- 类型
- 上市公司
- 领域
- biotechnology、hyaluronidase、rHuPH20和subcutaneous biologics
地点
Halozyme, Inc.员工
-
Louise Brandy
-
Amit Paz
Build, transform, grow, deliver. Supporting the delivery of innovative therapies to patients with value-oriented supply chain management.
-
Lisa Hertel
Senior Director, FP&A at Outset Medical
-
Joy Breed
Experienced, result-oriented technology executive, focused on Healthcare Informatics. Management of complex IT solutions, PMO, Dev teams, Tech Ops &…
动态
-
Earlier this week, Halozyme full year 2024 record revenue, exceeding its financial guidance for royalty revenue, adjusted EBITDA and Non-GAAP diluted EPS. The significant growth achieved throughout the year culminated in two important milestones for the Company: achievement of more than $1 billion in total revenue and reaching a cumulative one million patients with our ENHANZE drug delivery technology. Additional highlights include: ? Record full year 2024 total revenue increased 22% YOY to $1,015 million and record royalty revenue exceeded guidance increasing 27% YOY to $571 million ? Full year 2024 net income increased 58% YOY to $444 million; GAAP EPS increased 63% YOY to $3.43; adjusted EBITDA increased 48% YOY to $632 million and non-GAAP EPS increased 53% YOY to $4.231, both exceeding guidance ? Reiterating 2025 financial guidance ranges for total revenue of $1,150 - 1,225 million, representing YOY growth of 13% - 21%, adjusted EBITDA of $755 - $805 million, representing YOY growth of 19% - 27% and non-GAAP diluted EPS of $4.95 - $5.35, representing YOY growth of 17% - 26%1 More details are available here: https://ow.ly/LOfO50V3J4k Footnotes: 1. Amounts relate to amortization of the inventory step-up associated with purchase accounting for the Antares acquisition.
-
-
Yesterday, we hosted an Investor Conference Call during which we reiterated our 2024 financial guidance and raised 2025 and multi-year financial guidance. Highlights include: ? We reported preliminary 2024 unaudited estimated ranges consistent with previous financial guidance ? We raised 2025 financial guidance ranges for total revenue to $1,150 - $1,225 million, representing YoY growth of 16% - 23%; adjusted EBITDA of $755 - $805 million, representing YoY growth of 24% - 32%; and non-GAAP diluted EPS of $4.95 - $5.35, representing YoY growth of 21% - 30% ? Announced a new $250 million accelerated share repurchase For additional information, please visit: https://ow.ly/y7O850UCPS7
-
-
We’re closing out 2024 with some exciting news from our partners argenx, Bristol Myers Squibb and Takeda. Check out our latest news here: https://ow.ly/hrvS50UyrHp We appreciate the opportunity to continue to provide patients with more flexible treatment options with our innovative drug delivery technology and look forward to continuing to support patients and our partners in 2025 and beyond. Happy New Year!
-
Members of the executive leadership team are scheduled to present and host investor meetings at the Piper Sandler 36th Annual Healthcare Conference and the 7th Annual Evercore ISI HealthCONx Conference. To learn more: https://ow.ly/aJjg50Ukb0K
-
-
Last week, Halozyme reported financial and operating results for the third quarter and provided an update on our recent corporate activities and outlook. Highlights include: ? Total Revenue Increased 34% YOY to $290 million and Royalty Revenue Increased 36% YOY to $155 million ? Net Income Increased 67% YOY to $137 million and Adjusted EBITDA Increased 60% YOY to $184 million ? GAAP Diluted EPS Increased 72% YOY to $1.05 and Non-GAAP Diluted EPS Increased 69% YOY to $1.271 ? Raised 2024 Financial Guidance Ranges for Total Revenue of $970-$1,020 million, Representing YOY Growth of 17%-23%, Adjusted EBITDA of $595-$625 million, Representing YOY Growth of 40%-47%, and Non-GAAP Diluted EPS of $4.00-$4.20, Representing YOY Growth of 44%-52% More details are available here: https://ow.ly/u4yj50TZPeN Footnotes: 1. Reconciliations between GAAP reported and non-GAAP financial information for actual results are provided at the end.
-
-
Halozyme to Report Third Quarter 2024 Financial and Operating Results Earlier today, we announced that we will share our third quarter 2024 financial and operating results on Thursday, October 31 following the close of trading. https://ow.ly/LRpK50TS8pR
-
-
Attending PDA Universe of Pre-Filled Syringes and Injection Devices Conference 2024 this week? Join David Kang at 10:55 today to learn a more about using a Miniature Pig as a Preclinical Model to Predict the Clinical Injection Times of a 10 mL High-volume Auto-injector (HVAI) with Recombinant Human Hyaluronidase (rHuPH20). Have questions? Stop by booth #925 to learn more. #PDAups #subcutaneous #Halozyme
-
-
Attending PDA Universe of Pre-Filled Syringes and Injection Devices Conference 2024 tomorrow? Join David Kang at 11:30 to learn more about Challenges and Opportunities with Rapid Handheld Injections (> 2mL) and the Clinical Tolerability of a 10 mL High-Volume Auto-Injector. Have questions? Stop by booth #925 to learn more. #PDAups #subcutaneous #HVAI #Halozyme
-
-
Join us at Sexual Medicine Society of North America (SMSNA) tomorrow, Friday, October 18 at 7 am to learn how testosterone replacement may fit into your treatment approach. #halozyme #SMSNA24
-